SANGENTRI
DEAD

Serial Number

90382648

Owner

SAREPTA THERAPEUTICS, INC.

Attorney

Maury M. Tepper, III

Filing Date

Dec 15, 2020

Add to watchlist:

No watchlists yet
View on USPTO

SANGENTRI Trademark

Serial Number: 90382648

SANGENTRI is a trademark filed by SAREPTA THERAPEUTICS, INC. on December 15, 2020. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

SAREPTA THERAPEUTICS, INC. (109 trademarks)

215 FIRST STREET, SUITE 7
CAMBRIDGE, MA 02142

Entity Type: 03

Trademark Details

Filing Date

December 15, 2020

Registration Date

Not Registered

Published for Opposition

July 13, 2021

Goods & Services

Pharmaceutical preparations for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Pharmaceutical preparations based on morpholino oligomer technology platform for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders, and for the regulation of protein production; Pharmaceutical preparations that modulate RNA expression for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders, and for the regulation of protein production; Gene therapy products, namely, gene delivery pharmaceuticals; Pharmaceutical preparations for gene therapy, gene editing, and genome editing; Gene therapy products in the nature of pharmaceuticals for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Biological preparations for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Viruses, viral vectors and viral constructs for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Pharmaceutical preparations, biological preparations and gene therapy products in the nature of pharmaceutical and biological preparations for the treatment of genetic disorders and diseases

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Jul 12, 2024 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Jun 3, 2024 ABN6
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Oct 31, 2023 EXRA
SOU EXTENSION 4 GRANTED
Oct 27, 2023 EX4G
SOU EXTENSION 4 FILED
Oct 27, 2023 EXT4
SOU TEAS EXTENSION RECEIVED
Oct 27, 2023 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Apr 20, 2023 EXRA
SOU EXTENSION 3 GRANTED
Apr 18, 2023 EX3G
SOU EXTENSION 3 FILED
Apr 18, 2023 EXT3
SOU TEAS EXTENSION RECEIVED
Apr 18, 2023 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Nov 3, 2022 EXRA
SOU EXTENSION 2 GRANTED
Nov 1, 2022 EX2G
SOU EXTENSION 2 FILED
Nov 1, 2022 EXT2
SOU TEAS EXTENSION RECEIVED
Nov 1, 2022 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Apr 29, 2022 EXRA
SOU EXTENSION 1 GRANTED
Apr 27, 2022 EX1G
SOU EXTENSION 1 FILED
Apr 27, 2022 EXT1
SOU TEAS EXTENSION RECEIVED
Apr 27, 2022 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Nov 2, 2021 NOAM
EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
Sep 22, 2021 ETOP
EXTENSION OF TIME TO OPPOSE RECEIVED
Aug 11, 2021 ETOF
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jul 13, 2021 NPUB
PUBLISHED FOR OPPOSITION
Jul 13, 2021 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jun 23, 2021 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jun 4, 2021 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 3, 2021 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 3, 2021 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jun 3, 2021 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
May 31, 2021 GNRN
NON-FINAL ACTION E-MAILED
May 31, 2021 GNRT
NON-FINAL ACTION WRITTEN
May 31, 2021 CNRT
ASSIGNED TO EXAMINER
May 29, 2021 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Feb 23, 2021 NWOS
NEW APPLICATION ENTERED
Dec 18, 2020 NWAP